Incretin & metabolic research compounds
Pramlintide
Also known as Symlin
A synthetic analogue of the pancreatic hormone amylin, the first approved amylinomimetic.
In 60 seconds
Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients.
- Reviews pramlintide as the first amylinomimetic, approved in 2005 as an insulin adjunct.
- Describes amylin’s glucagon, gastric-emptying and food-intake effects and the clinical data for pramlintide.
- A randomised study in migraine patients found pramlintide induced migraine-like attacks.
Mechanism
Amylin is co-secreted with insulin; it lowers post-meal glucose by suppressing glucagon, slowing gastric emptying and reducing food intake. Pramlintide substitutes prolines to stop native amylin’s tendency to aggregate.
Research status
Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide.
Key studies
Reviews pramlintide as the first amylinomimetic, approved in 2005 as an insulin adjunct.
Pramlintide acetate — Am J Health Syst Pharm, 2005 · PMID 16278328
Describes amylin’s glucagon, gastric-emptying and food-intake effects and the clinical data for pramlintide.
Pramlintide in the treatment of type 1 and type 2 diabetes mellitus — Clin Ther, 2005 · PMID 16330288
A randomised study in migraine patients found pramlintide induced migraine-like attacks.
Amylin Analog Pramlintide Induces Migraine-like Attacks in Patients — Ann Neurol, 2021 · PMID 33772845
Studied amylin and pramlintide effects on amyloid precursor protein processing in lipid rafts.
Amylin and pramlintide modulate γ-secretase level and APP processing in lipid rafts — Sci Rep, 2020 · PMID 32111883
Safety signals in the literature
Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Pramlintide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Pramlintide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Pramlintide?
A synthetic analogue of the pancreatic hormone amylin, the first approved amylinomimetic. Amylin is co-secreted with insulin; it lowers post-meal glucose by suppressing glucagon, slowing gastric emptying and reducing food intake. Pramlintide substitutes prolines to stop native amylin’s tendency to aggregate.
What is the research status of Pramlintide?
Approved (2005, US) as an adjunct to mealtime insulin in type 1 and type 2 diabetes. The scientific ancestor of cagrilintide.
What safety signals are reported for Pramlintide?
Hypoglycaemia risk when combined with insulin is the key labelled concern; a randomised study found it could provoke migraine-like attacks in migraine patients.
Does Living Water Labs stock Pramlintide?
Not at present. Pramlintide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
